Abstract
The ability to affect eukaryotic and prokaryotic cellular growth, signaling and differentiation is a continuing focus in the pharmaceutical industry. The fundamental ability to affect these cellular processes is inherent in lactones. Lactones, which are ubiquitous in nature, reflect a broad phylogenetic diversity indicative of their ability to act as simple alkylating compounds, with their in situ activities falling into one of two categories, i.e., protect or conquer. Medically, their utility as pharmaceutical agents range from that of antimicrobial to anti-neoplastic agent depending on the functional groups attached.
Keywords: lactones, dna polymerases, human immunodeficiency virus type 1 (hiv-1) reverse transcriptase, cytokines
Mini-Reviews in Medicinal Chemistry
Title: Lactones: Generic Inhibitors of Enzymes?
Volume: 5 Issue: 1
Author(s): Monika I. Konaklieva and Balbina J. Plotkin
Affiliation:
Keywords: lactones, dna polymerases, human immunodeficiency virus type 1 (hiv-1) reverse transcriptase, cytokines
Abstract: The ability to affect eukaryotic and prokaryotic cellular growth, signaling and differentiation is a continuing focus in the pharmaceutical industry. The fundamental ability to affect these cellular processes is inherent in lactones. Lactones, which are ubiquitous in nature, reflect a broad phylogenetic diversity indicative of their ability to act as simple alkylating compounds, with their in situ activities falling into one of two categories, i.e., protect or conquer. Medically, their utility as pharmaceutical agents range from that of antimicrobial to anti-neoplastic agent depending on the functional groups attached.
Export Options
About this article
Cite this article as:
Konaklieva I. Monika and Plotkin J. Balbina, Lactones: Generic Inhibitors of Enzymes?, Mini-Reviews in Medicinal Chemistry 2005; 5 (1) . https://dx.doi.org/10.2174/1389557053402828
DOI https://dx.doi.org/10.2174/1389557053402828 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry Mechanisms of Esophageal Protection, Gastroprotection and Ulcer Healing by Melatonin. Implications for the Therapeutic use of Melatonin in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on Nanotechnology Role of the Mitochondrial Permeability Transition in Apoptotic and Necrotic Death After Ischemia / Reperfusion Injury to Hepatocytes
Current Molecular Medicine CD93: Recent Advances and Implications in Disease
Current Drug Targets Wip1-Deficient Neutrophils Significantly Promote Intestinal Ischemia/Reperfusion Injury in Mice
Current Molecular Medicine Preface
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Indian Spices for Healthy Heart - An Overview
Current Cardiology Reviews The Expression of Activity-Dependent Neuroprotective Protein (ADNP) is Regulated by Brain Damage and Treatment of Mice with the ADNP Derived Peptide, NAP, Reduces the Severity of Traumatic Head Injury
Current Alzheimer Research Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Current Pharmaceutical Design Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Thromboxane A2 Receptor Blockade Prevents Atherosclerotic Process by its Anti-Inflammatory Effect
Vascular Disease Prevention (Discontinued) Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry Opioids: Old Drugs for Potential New Applications
Current Pharmaceutical Design Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology